BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Di Lernia V. Adalimumab for treating childhood plaque psoriasis: a clinical trial evaluation. Expert Opinion on Biological Therapy 2017;17:1553-6. [DOI: 10.1080/14712598.2017.1369950] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Di Lernia V, Bianchi L, Guerriero C, Stingeni L, Gisondi P, Filoni A, Guarneri C, Belloni Fortina A, Lasagni C, Simonetti O, Neri I, Zangrilli A, Moretta G, Hansel K, Casanova DM, Girolomoni G, Cannavò SP, Bonamonte D. Adalimumab in severe plaque psoriasis of childhood: A multi-center, retrospective real-life study up to 52 weeks observation. Dermatol Ther 2019;32:e13091. [PMID: 31579972 DOI: 10.1111/dth.13091] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
2 Sator P. Safety and tolerability of adalimumab for the treatment of psoriasis: a review summarizing 15 years of real-life experience. Ther Adv Chronic Dis 2018;9:147-58. [PMID: 30065812 DOI: 10.1177/2040622318772705] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
3 Lanna C, Zangrilli A, Bavetta M, Campione E, Bianchi L. Efficacy and safety of adalimumab in difficult‐to‐treat psoriasis. Dermatologic Therapy 2020;33. [DOI: 10.1111/dth.13374] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
4 Libon F, Lebas E, De Schaetzen V, Sabatiello M, De Schepper S, Nikkels AF. Biologicals for moderate-to-severe plaque type psoriasis in pediatric patients. Expert Rev Clin Immunol 2021;:1-9. [PMID: 34328370 DOI: 10.1080/1744666X.2021.1958675] [Reference Citation Analysis]
5 Lavaud J, Mahé E. Scores de sévérité dans le psoriasis de l’enfant : revue systématique de la littérature. Annales de Dermatologie et de Vénéréologie 2019;146:771-82. [DOI: 10.1016/j.annder.2019.03.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
6 Lanna C, Zangrilli A, Bavetta M, Diluvio L, Campione E, Bianchi L. Skin advanced glycation end products as a diagnostic and monitoring tool among psoriatic patients: how the therapy helps reduce cardiovascular disease risk. Int J Dermatol 2021. [PMID: 34432309 DOI: 10.1111/ijd.15851] [Reference Citation Analysis]
7 Zangrilli A, Bavetta M, Bianchi L. Adalimumab in children and adolescents with severe plaque psoriasis: a safety evaluation. Expert Opin Drug Saf 2020;19:433-8. [PMID: 32250180 DOI: 10.1080/14740338.2020.1752659] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]